Zdrowie i gospodarka · 28/09/2015

FDA Announces Fee Rate for Rare Pediatric Disease Priority Review Voucher for Fiscal Year 2016

The US Food and Drug Administration (FDA) has set the fee rate for using a rare pediatric disease priority review voucher for fiscal year 2016, based on the average costs incurred by the agency in reviewing human drug applications in the previous year.